STOCK TITAN
  1. Home
  2. News
  3. BLUE

Bluebird bio Inc - BLUE STOCK NEWS

Welcome to our dedicated news page for Bluebird bio (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on Bluebird bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bluebird bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bluebird bio's position in the market.

News
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) announced new and updated efficacy, safety, and health-related quality of life data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease. The data presented at ASH show that lovo-cel has the potential to address the underlying cause of sickle cell disease and provide robust clinical benefits for patients, with 94% complete resolution of sVOEs and 88% complete resolution of VOEs achieved in evaluable patients. The therapy has shown a durable impact on the underlying cause of sickle cell disease, with reductions in VOE frequency and severity, and significant improvements in hemolysis markers and health-related quality of life measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) announced the U.S. commercial infrastructure for LYFGENIA, an FDA-approved gene therapy for sickle cell disease. LYFGENIA launch includes outcomes-based contract offerings for payers and a personalized patient support program. The wholesale acquisition cost of LYFGENIA is set at $3.1M. The therapy aims to deliver robust and sustained clinical benefits, reducing or eliminating vaso-occlusive events, and enhancing patients' healthcare utilization, future earnings, and life opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.54%
Tags
none
-
News
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
Rhea-AI Summary
bluebird bio, Inc. (Nasdaq: BLUE) has received FDA approval for LYFGENIA™ (lovotibeglogene autotemcel), also known as lovo-cel, for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). LYFGENIA is a one-time gene therapy that has the potential to resolve vaso-occlusive events and is custom-designed to treat the underlying cause of sickle cell disease. The approval marks bluebird’s third ex vivo gene therapy approved by the FDA for a rare genetic disease and second FDA approval for an inherited hemoglobin disorder, cementing their position as a gene therapy leader.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-40.54%
Tags
fda approval
News
Engine Capital Sends Letter to 2seventy’s Board of Directors Outlining Steps to Maximize Shareholder Value
Rhea-AI Summary
Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.’s (Nasdaq: TSVT) outstanding shares, believes that the company could be conservatively worth ~$9 per share if it exclusively focuses on its most-valuable asset Abecma, reduces corporate overhead and makes improvements to the composition of the management team and board. The company is currently trading at a market capitalization of just $100 million, despite having a cash balance of $284 million and a 50% profit interest in Abecma that is likely worth at least a few hundred million dollars.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.55%
Tags
management
-
News
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
Rhea-AI Summary
bluebird bio, Inc. (NASDAQ: BLUE) reported continued strong commercial launches for ZYNTEGLO® and SKYSONA®, with 22 patient starts across both programs to date. The company ended the quarter with $227M in cash, cash equivalents, marketable securities, and restricted cash. They also entered into an advance agreement to sell a priority review voucher, if granted, for $103 million, potentially strengthening their cash position. Management will host a conference call at 8:00AM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.27%
Tags
earnings
-
News
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
Rhea-AI Summary
bluebird bio, Inc. will present new long-term efficacy, safety, and health-related quality of life data from its gene therapy programs for sickle cell disease and beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The data demonstrate sustained improvements in patient outcomes and the maturity of the gene therapies. The company also announced that the FDA accepted the lovo-cel Biologics Licensing Application for Priority Review.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
conferences
News
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
Rhea-AI Summary
bluebird bio has entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) in connection with the potential approval of lovo-cel for sickle cell disease. The Company will receive $103 million upon closing of the sale, contingent upon FDA approval of the biologics license application (BLA) for lovo-cel and granting of the PRV. The BLA has a goal date of December 20, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.3%
Tags
none
-
News
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
Rhea-AI Summary
bluebird bio, Inc. to host conference call to discuss Q3 2023 financial results and business updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
conferences earnings
-
News
bluebird bio Announces September Investor Events
Rhea-AI Summary
bluebird bio to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
none
News
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
Rhea-AI Summary
Bluebird bio, Inc. (Nasdaq: BLUE) announced that the FDA will not schedule an advisory committee meeting for its gene therapy, lovo-cel, for sickle cell disease. The BLA for lovo-cel has a PDUFA goal date of December 20, 2023. The company remains confident in the robustness of its BLA package and is focused on the FDA's review for a decision by the end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.38%
Tags
none
Stock BLUE logo
Bluebird bio Inc

Nasdaq:BLUE

BLUE Rankings

#3862 Ranked by Market Cap
#4831 Ranked by Stock Gains
N/A Ranked by Dividends

BLUE Stock Data

190.87M
108.82M
0.38%
65.11%
15.43%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Somerville

About BLUE

we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.